Mark S Bednarz

This inventor holds 6 USPTO granted patents, plus 2 CIPO patents and 4 EPO patents. Top assignee: Lexicon Pharmaceuticals, Inc.. Active years: 2011-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark S Bednarz. Retrieved from https://idiyas.com/inventor/mark-s-bednarz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Yardley, PA (US) (2011 - 2014)
Lower Makefield Township, PA (US) (2021)

Company Filing History:

6 out of 89

Lexicon Pharmaceuticals, Inc.

patents

Years Active: 2011-2021

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10968192 - Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis (2021-04-06),

2. 8653094 - Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use (2014-02-18),

3. 8575362 - Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds (2013-11-05),

4. 8193204 - Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use (2012-06-05),

5. 7968729 - 1-phenyl-1H-pyrazole-based compounds (2011-06-28),

6. 7951941 - Process for preparing 5-alkyl-7H-pyrrolo[2,3-d] pyrimindine-2-ols (2011-05-31),

Title: Innovations of Mark S Bednarz

Introduction

Mark S Bednarz is a notable inventor based in Yardley, PA (US). He has made significant contributions to the field of pharmaceuticals, holding a total of six patents. His work primarily focuses on the development of crystalline solid forms and methods of synthesis for various compounds.

Latest Patents

Among his latest patents, Bednarz has developed crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis. Additionally, he has disclosed methods of preparing solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and salts thereof.

Career Highlights

Mark S Bednarz is currently associated with Lexicon Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical sector. His expertise in the synthesis of complex compounds has positioned him as a valuable asset in his field.

Collaborations

Throughout his career, Bednarz has collaborated with notable colleagues such as Ramanaiah C Kanamarlapudi and Wenxue Wu. These collaborations have further enhanced the scope and impact of his research.

Conclusion

Mark S Bednarz is a distinguished inventor whose work in pharmaceuticals has led to multiple patents and significant advancements in drug development. His contributions continue to influence the industry and pave the way for future innovations.

Profile summary based on public USPTO records.